Project Grant HT94252310605

This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $506,309 to the Trustees of Indiana University (doing business as Indiana University Indianapolis) to conduct research on the regulation of ovarian cancer metastasis by microenvironment-induced chromatin accessibility and c-Jun activation. The key objectives of this 5-year research project are to determine the mechanism by which microenvironmental signals activate the...

The National Cancer Institute (NCI) awarded a $584,081 Project Grant under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394) to Sanford Research, a non-profit biomedical research organization located in Fargo, North Dakota. The purpose of this 5-year project is to elucidate the spatiotemporal dynamics of the extracellular matrix (ECM) in response to platinum treatment in ovarian cancer, with the goal of better understanding how changes in the ECM contribute to...

This $167,500 Project Grant was awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Feinstein Institutes For Medical Research, a non-profit medical research organization located in Manhasset, New York. The grant supports research to understand the communication between cancer cells and cancer-associated fibroblasts in chronic lymphocytic leukemia (CLL). The goal is to identify potential therapeutic targets in the CLL tumor microenvironment to improve...

The University of Pittsburgh received a $1,373,308 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to conduct research on "ACYLCARNITINE METABOLISM IN OVARIAN CANCER CHEMORESISTANCE." The project aims to: 1) quantitatively and mechanistically map the acetylcarnitine-dependent histone acetylation axis and its contribution to homologous recombination (HR)-mediated DNA repair; and 2) interrogate whether interventions that suppress intracellular...

The National Cancer Institute (NCI) awarded a $151,000 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to The Medical University of South Carolina (MUSC) to investigate the role of polyploid cancer cells in high-grade serous ovarian carcinoma (HGSOC). The project aims to: 1) Define essential genes for the polyploid cancer cell lifecycle and its critical transition stages using CRISPR-Cas9 screening, and 2) Determine the expression of putative polyploid cancer...

The National Cancer Institute awarded a $102,984 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The Trustees of Columbia University in the City of New York, Health Sciences Division. The grant, titled "Dissecting a Novel Role of FAK in Modulating Immunity During Metastatic Reactivation and Progression," aims to investigate the role of focal adhesion kinase (FAK) in promoting metastatic reactivation and immune evasion in cancer. The research will leverage in...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is funding research by the University of Texas MD Anderson Cancer Center to investigate the mechanisms underlying cross-resistance to platinum-based chemotherapy and PARP inhibitors in high-grade serous ovarian cancer (HGSOC). The $164,000 award, spanning from September 1, 2025 to August 31, 2027, will utilize a novel mouse model and molecular barcoding technology to characterize the evolution...

The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $230,711 project grant to The Trustees of Columbia University in the City of New York, Health Sciences Division, to conduct research on overcoming resistance to hedgehog inhibitor treatments in basal cell carcinomas. The 2-year project aims to elucidate the role of the BRD9 chromatin remodeling complex in promoting an immunosuppressive tumor microenvironment that drives resistance to hedgehog-targeted therapies....

The University of Pittsburgh received a $180,632 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to conduct research on halting breast cancer metastasis by blocking cancer-mesenchymal stem cell (MSC) engulfment. The research aims to discover and validate compounds that can inhibit this cancer-MSC engulfment process, as it has been shown to increase cancer cell tumorigenicity, metastatic potential, and resistance to chemotherapy. The 2-year project...

The National Cancer Institute (NCI) awarded a $629,341 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to Colorado State University (CSU) on September 12, 2025. The grant supports research to understand how focal adhesion kinase (FAK) signaling in osteosarcoma (OS) tumor cells and lung fibroblasts shapes the immune composition of the lung metastatic tumor microenvironment. The objective is to determine if molecular targeting of FAK can improve the response...